Engineered lymphocytes to treat dinitrobenzene sulphonic acid colitis in mice.

Détails

ID Serval
serval:BIB_46F6461CD001
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Editorial
Collection
Publications
Institution
Titre
Engineered lymphocytes to treat dinitrobenzene sulphonic acid colitis in mice.
Périodique
European journal of gastroenterology & hepatology
Auteur⸱e⸱s
Felley C., Michetti P.
ISSN
0954-691X (Print)
ISSN-L
0954-691X
Statut éditorial
Publié
Date de publication
12/2003
Peer-reviewed
Oui
Volume
15
Numéro
12
Pages
1253-1255
Langue
anglais
Notes
Publication types: Comment ; Journal Article
Publication Status: ppublish
Résumé
Current treatments of inflammatory bowel diseases are limited either by their lack of efficacy or their potential toxicity. In recent years, major advances have been obtained by the development of biological therapies. However, these types of treatment are systemic and can lead to serious adverse events. The new venue of local biological treatments would be most welcome. In this issue of the Journal, Castagliuolo et al. show that lymphocytes engineered to produce TGF-beta1 can reverse dinitrobenzene sulphonic acid-induced colitis in mice. These engineered lymphocytes selectively accumulate in the intestinal mucosa due to the homing properties of their alpha4beta7 integrins, a ligand for MAdCAM1. A local treatment restricted to the inflamed mucosa can thus be obtained. This opens a brand new area of research with the hope of restoring the immunoregulatory balance selectively in the inflamed tissues.
Mots-clé
Animals, Benzenesulfonates, Colitis/chemically induced, Colitis/therapy, Genetic Therapy/methods, Lymphocyte Transfusion/methods, Lymphocytes/metabolism, Mice, Transforming Growth Factor beta/biosynthesis, Transforming Growth Factor beta1
Pubmed
Web of science
Open Access
Oui
Création de la notice
25/01/2008 16:59
Dernière modification de la notice
09/04/2024 7:13
Données d'usage